Kelly Scaggs Campen
Examiner (ID: 2758, Phone: (571)272-6740 , Office: P/3691 )
Most Active Art Unit | 3691 |
Art Unit(s) | 3624, 2165, 2164, 3312, 3738, 3691 |
Total Applications | 1052 |
Issued Applications | 501 |
Pending Applications | 228 |
Abandoned Applications | 322 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16343642
[patent_doc_number] => 20200308292
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => METHODS AND COMPOSITIONS FOR INCREASING ENZYME ACTIVITY IN THE CNS
[patent_app_type] => utility
[patent_app_number] => 16/905292
[patent_app_country] => US
[patent_app_date] => 2020-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31733
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -163
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16905292
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/905292 | METHODS AND COMPOSITIONS FOR INCREASING ENZYME ACTIVITY IN THE CNS | Jun 17, 2020 | Abandoned |
Array
(
[id] => 16469579
[patent_doc_number] => 20200371116
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => ANTIBODIES TO DISULFATED HEPARIN DISACCHARIDE IN THE DIAGNOSIS OF NEUROPATHY
[patent_app_type] => utility
[patent_app_number] => 16/895970
[patent_app_country] => US
[patent_app_date] => 2020-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6822
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16895970
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/895970 | ANTIBODIES TO DISULFATED HEPARIN DISACCHARIDE IN THE DIAGNOSIS OF NEUROPATHY | Jun 7, 2020 | Abandoned |
Array
(
[id] => 16526582
[patent_doc_number] => 20200400662
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => METHODS AND REAGENTS FOR REDUCING THE INTERFERENCE OF DRUGS THAT BIND CD47 IN SEROLOGICAL ASSAYS
[patent_app_type] => utility
[patent_app_number] => 16/894468
[patent_app_country] => US
[patent_app_date] => 2020-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18295
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16894468
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/894468 | METHODS AND REAGENTS FOR REDUCING THE INTERFERENCE OF DRUGS THAT BIND CD47 IN SEROLOGICAL ASSAYS | Jun 4, 2020 | Pending |
Array
(
[id] => 16763534
[patent_doc_number] => 20210109115
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-15
[patent_title] => EXOSOMAL TAU AS A BIOMARKER FOR BRAIN DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/883624
[patent_app_country] => US
[patent_app_date] => 2020-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79979
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16883624
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/883624 | EXOSOMAL TAU AS A BIOMARKER FOR BRAIN DISORDERS | May 25, 2020 | Abandoned |
Array
(
[id] => 16569179
[patent_doc_number] => 20210008185
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => Treatment and Prophylaxis of Amyloidosis
[patent_app_type] => utility
[patent_app_number] => 16/879286
[patent_app_country] => US
[patent_app_date] => 2020-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50005
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16879286
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/879286 | Treatment and Prophylaxis of Amyloidosis | May 19, 2020 | Abandoned |
Array
(
[id] => 16807891
[patent_doc_number] => 20210130444
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
[patent_app_type] => utility
[patent_app_number] => 16/877103
[patent_app_country] => US
[patent_app_date] => 2020-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22199
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16877103
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/877103 | Compositions and methods for the treatment of neuromyelitis optica | May 17, 2020 | Issued |
Array
(
[id] => 17453035
[patent_doc_number] => 11267880
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-08
[patent_title] => Anti-Sema3A antibodies and their uses for treating eye or ocular diseases
[patent_app_type] => utility
[patent_app_number] => 16/869618
[patent_app_country] => US
[patent_app_date] => 2020-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 7
[patent_no_of_words] => 19983
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16869618
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/869618 | Anti-Sema3A antibodies and their uses for treating eye or ocular diseases | May 7, 2020 | Issued |
Array
(
[id] => 16523818
[patent_doc_number] => 20200397898
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => HUMAN ANTIBODIES AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/869344
[patent_app_country] => US
[patent_app_date] => 2020-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50968
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16869344
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/869344 | HUMAN ANTIBODIES AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASE | May 6, 2020 | Pending |
Array
(
[id] => 16523777
[patent_doc_number] => 20200397857
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => METHODS AND COMPOSITIONS FOR PROMOTING OPC DIFFERENTIATION AND REMYELINATION USING RECEPTOR ASSOCIATED PROTEIN (RAP)
[patent_app_type] => utility
[patent_app_number] => 16/867058
[patent_app_country] => US
[patent_app_date] => 2020-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9311
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867058
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/867058 | METHODS AND COMPOSITIONS FOR PROMOTING OPC DIFFERENTIATION AND REMYELINATION USING RECEPTOR ASSOCIATED PROTEIN (RAP) | May 4, 2020 | Pending |
Array
(
[id] => 16343612
[patent_doc_number] => 20200308262
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING VIRUS-ASSOCIATED INFLAMMATION
[patent_app_type] => utility
[patent_app_number] => 16/856407
[patent_app_country] => US
[patent_app_date] => 2020-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42018
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16856407
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/856407 | Methods and compositions for treating virus-associated inflammation | Apr 22, 2020 | Issued |
Array
(
[id] => 16398780
[patent_doc_number] => 20200339638
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => Modulators of Chromosome 9 Open Reading Frame 72 Gene Expression and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 16/856774
[patent_app_country] => US
[patent_app_date] => 2020-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18656
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16856774
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/856774 | Modulators of Chromosome 9 Open Reading Frame 72 Gene Expression and Uses Thereof | Apr 22, 2020 | Pending |
Array
(
[id] => 16533326
[patent_doc_number] => 10875910
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-12-29
[patent_title] => Antibodies recognizing alpha-synuclein
[patent_app_type] => utility
[patent_app_number] => 16/856855
[patent_app_country] => US
[patent_app_date] => 2020-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 17394
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16856855
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/856855 | Antibodies recognizing alpha-synuclein | Apr 22, 2020 | Issued |
Array
(
[id] => 16391070
[patent_doc_number] => 20200332011
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-22
[patent_title] => Modified anti-PD-L1 Antibody and Methods and Uses for Treating a Neurodegenerative Disease
[patent_app_type] => utility
[patent_app_number] => 16/852508
[patent_app_country] => US
[patent_app_date] => 2020-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79106
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16852508
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/852508 | Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease | Apr 18, 2020 | Issued |
Array
(
[id] => 16397290
[patent_doc_number] => 20200338148
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/846210
[patent_app_country] => US
[patent_app_date] => 2020-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34277
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16846210
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/846210 | Gene therapies for lysosomal disorders | Apr 9, 2020 | Issued |
Array
(
[id] => 16296357
[patent_doc_number] => 20200282080
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/841539
[patent_app_country] => US
[patent_app_date] => 2020-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16940
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841539
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/841539 | Gene therapies for lysosomal disorders | Apr 5, 2020 | Issued |
Array
(
[id] => 16296357
[patent_doc_number] => 20200282080
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/841539
[patent_app_country] => US
[patent_app_date] => 2020-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16940
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841539
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/841539 | Gene therapies for lysosomal disorders | Apr 5, 2020 | Issued |
Array
(
[id] => 16296357
[patent_doc_number] => 20200282080
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/841539
[patent_app_country] => US
[patent_app_date] => 2020-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16940
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841539
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/841539 | Gene therapies for lysosomal disorders | Apr 5, 2020 | Issued |
Array
(
[id] => 16296357
[patent_doc_number] => 20200282080
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => GENE THERAPIES FOR LYSOSOMAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/841539
[patent_app_country] => US
[patent_app_date] => 2020-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16940
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841539
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/841539 | Gene therapies for lysosomal disorders | Apr 5, 2020 | Issued |
Array
(
[id] => 16621534
[patent_doc_number] => 20210040187
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-11
[patent_title] => NANOBODIES SUITABLE FOR NEURON REGENERATION THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/839009
[patent_app_country] => US
[patent_app_date] => 2020-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24057
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839009
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/839009 | Nanobodies suitable for neuron regeneration therapy | Apr 1, 2020 | Issued |
Array
(
[id] => 16236879
[patent_doc_number] => 20200254113
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => FUSION PROTEINS FOR DELIVERY OF GDNF TO THE CNS
[patent_app_type] => utility
[patent_app_number] => 16/828557
[patent_app_country] => US
[patent_app_date] => 2020-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40057
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828557
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/828557 | FUSION PROTEINS FOR DELIVERY OF GDNF TO THE CNS | Mar 23, 2020 | Abandoned |